Penumbra, Inc. (NYSE:PEN) Director Thomas Wilder Sells 360 Shares of Stock

Penumbra, Inc. (NYSE:PEN) Director Thomas Wilder sold 360 shares of the company’s stock in a transaction dated Wednesday, April 2nd. The stock was sold at an average price of $266.93, for a total transaction of $96,094.80. Following the transaction, the director now owns 4,692 shares of the company’s stock, valued at $1,252,435.56. This represents a 7.13 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Thomas Wilder also recently made the following trade(s):

• On Monday, March 31st, Thomas Wilder sold 360 shares of Penumbra stock. The shares were sold at an average price of $264.58, for a total transaction of $95,248.80.

Penumbra Price Performance

NYSE PEN opened at $262.37 on Friday. Penumbra, Inc. has a 1 year low of $148.00 and a 1 year high of $310.00. The business’s fifty day moving average is $274.48 and its two-hundred day moving average is $245.21. The stock has a market capitalization of $10.11 billion, a P/E ratio of 771.66, a P/E/G ratio of 2.83 and a beta of 0.51. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.25 and a current ratio of 6.01.

Penumbra (NYSE:PEN) last announced its earnings results on Tuesday, February 18th. The company reported $0.97 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.88 by $0.09. Penumbra had a return on equity of 9.74% and a net margin of 1.17%. The company had revenue of $315.52 million for the quarter, compared to analyst estimates of $311.63 million. On average, research analysts forecast that Penumbra, Inc. will post 3.67 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in PEN. UMB Bank n.a. raised its holdings in shares of Penumbra by 57.4% during the fourth quarter. UMB Bank n.a. now owns 192 shares of the company’s stock valued at $46,000 after acquiring an additional 70 shares during the period. Hurley Capital LLC acquired a new stake in Penumbra during the 4th quarter valued at $56,000. Huntington National Bank lifted its holdings in shares of Penumbra by 138.7% in the fourth quarter. Huntington National Bank now owns 265 shares of the company’s stock valued at $63,000 after purchasing an additional 154 shares in the last quarter. Mather Group LLC. lifted its holdings in shares of Penumbra by 208.0% in the fourth quarter. Mather Group LLC. now owns 308 shares of the company’s stock valued at $73,000 after purchasing an additional 208 shares in the last quarter. Finally, Versant Capital Management Inc boosted its position in shares of Penumbra by 893.5% in the first quarter. Versant Capital Management Inc now owns 308 shares of the company’s stock worth $82,000 after buying an additional 277 shares during the period. 88.88% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on PEN shares. Royal Bank of Canada lifted their price target on Penumbra from $285.00 to $313.00 and gave the company an “outperform” rating in a report on Wednesday, February 19th. Needham & Company LLC reiterated a “hold” rating on shares of Penumbra in a research report on Wednesday, February 19th. StockNews.com lowered Penumbra from a “buy” rating to a “hold” rating in a report on Friday, February 28th. Morgan Stanley upped their price objective on shares of Penumbra from $240.00 to $260.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 19th. Finally, Citigroup raised their target price on shares of Penumbra from $220.00 to $245.00 and gave the company a “neutral” rating in a research note on Wednesday, December 11th. Four equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $294.47.

About Penumbra

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.